Biliary Tract Cancers: Is Laparoscopic Liver Resection Adequate?

2022 Year in Review: Cholangiocarcinoma — January 4, 2023

The safety and adequacy of laparoscopic liver surgery has not been well established in biliary tract cancers. An institutional retrospective matched cohort study identified patients in the Mayo Clinic’s institutional database who underwent laparoscopic versus open surgery and compared clinical operative and postoperative variables. Results from this study were shared at the 2022 International Hepato-Pancreato-Biliary Association World Congress.

A total of 87 patients were identified; 33 underwent laparoscopic surgery and 54 underwent open resection. The patients who underwent laparoscopic resections had significantly less blood loss, higher negative-margin resection rates, shorter length of stay, and lower number of harvested lymph nodes, and these patients were less likely to have major liver resection. There were no between-group differences in procedural time, tumor size, severe postoperative complications, need for adjuvant chemotherapy, or need for readmission.

The researchers concluded that “laparoscopic liver resections for GBC and iCCA are safe and appear to have at least some short-term benefits with appropriate patient selection and when these procedures are done by a high volume, experienced center. They also do not compromise any of the oncologic outcomes.”

Flavio Rocha, MD, FACS, FSSP, Physician-in-Chief of the Knight Cancer Institute, noted that these results were hypothesis-generating: “I do think the shorter operative procedures can certainly help patients get onto adjuvant therapy quicker, which we know ultimately is what they need to control micrometastatic disease after surgery.”

Source: Pery R, Starlinger P, Fiorentini G, et al. Laparoscopic versus open liver resections for gallbladder cancer and intrahepatic cholangiocarcinoma: the Mayo Clinic experience. International Hepato-Pancreato-Biliary Association World Congress 2022. Abstract FP10-5.

Related Items

Cross-Comparison of Clinical Trials Assessing Futibatinib and Pemigatinib versus Chemotherapy in Patients with CCA and FGFR2 Fusion or Other Rearrangements
2022 Year in Review: Cholangiocarcinoma
A comparison of clinical trials found progression-free survival with futibatinib to be significantly greater compared with chemotherapy and that trials favor futibatinib over pemigatinib for all efficacy parameters.
Utility of Liquid Biopsy for Identification of Molecular Alterations in Solid Tumors
2022 Year in Review: Cholangiocarcinoma
Real-world evidence supports a role for liquid biopsy in identifying molecular alterations and offering personalized treatment options, with IDH1 identified in a patient with cholangiocarcinoma.
Preliminary Analyses of QOL Data from the ABC-06 Clinical Trial
2022 Year in Review: Cholangiocarcinoma
Preliminary quality-of-life data suggest a potentially positive impact of L-folinic acid plus oxaliplatin plus 5-fluorouracil when used in conjunction with active symptom control.
NALIRICC Study of Nanoliposomal Irinotecan Combination Therapy in Metastatic BTC
2022 Year in Review: Cholangiocarcinoma
The NALIRICC study did not meet overall survival or progression-free survival end points, with nanoliposomal irinotecan plus 5-fluorouracil falling short in patients with metastatic biliary tract cancer.
Tislelizumab plus GemOx and Lenvatinib as a Conversion Therapy Regimen for Potentially Resectable BTCs
2022 Year in Review: Cholangiocarcinoma
The combination of tislelizumab, lenvatinib, and gemcitabine/oxaliplatin was shown to be promising as a conversion therapy for patients with potentially resectable locally advanced biliary tract cancer in this phase 2 study.
Health-Related QOL Study in Patients with CCA
2022 Year in Review: Cholangiocarcinoma
Study revealed increased financial toxicities in patients with cholangiocarcinoma enrolled in clinical trials and receiving targeted therapies.
Updated Analysis of the LUC2001 Study
2022 Year in Review: Cholangiocarcinoma
Erdafitinib was found to be associated with durable efficacy and manageable toxicity in Asian patients with advanced cholangiocarcinoma with FGFR alterations.
The Future of Neoadjuvant Chemotherapy for iCCA
2022 Year in Review: Cholangiocarcinoma
Study found lower rates of margin-positive resection of intrahepatic cholangiocarcinoma with neoadjuvant chemotherapy.
Mayo Clinic Study Assessed Impact of Neoadjuvant Chemoradiation in Patients with Unresectable Perihilar CCA
2022 Year in Review: Cholangiocarcinoma
Neoadjuvant chemoradiation was found to elicit no differences in survival among patients with unresectable perihilar cholangiocarcinoma.
Impact of Liver-Directed Radiation Therapy in Patients with Metastatic iCCA
2022 Year in Review: Cholangiocarcinoma
A single-institution study found that liver-directed radiation therapy was associated with favorable tumor-related liver failure and survival times in patients with metastatic intrahepatic or extrahepatic cholangiocarcinoma.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: